Parasvi S Patel

Dr. Parasvi S Patel

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Science Advances
Verified
Journal Article
Open access
AKAjinkya S. Kawale
Ajinkya S. Kawale
XRXiaojuan Ran
Xiaojuan Ran
PPParasvi S Patel
Parasvi S Patel
SSSneha Saxena
Sneha Saxena
MLMichael Lawrence
Michael Lawrence
LZLee Zou
Lee Zou
Mutation signatures associated with apolipoprotein B mRNA editing catalytic polypeptide-like 3A/B (APOBEC3A/B) cytidine deaminases are prevalent across cancers, implying their roles as mutagenic drivers during tumorigenesis and tumor evolution. APOBEC3A (A3A) expression induces DNA replication stress and increases the cellular dependency on the ataxia telangiectasia and Rad3-related (ATR) kinase for survival. Nonetheless, how A3A induces DNA replication stress remains unclear. We show that A3A induces replication stress without slowing replication forks. We find that A3A induces single-stranded DNA (ssDNA) gaps through PrimPol-mediated repriming. A3A-induced ssDNA gaps are repaired by multiple pathways involving ATR, RAD51, and translesion synthesis. Both ATR inhibition and trapping of poly(ADP-ribose) polymerase (PARP) on DNA by PARP inhibitor impair the repair of A3A-induced gaps, preferentially killing A3A-expressing cells. When used in combination, PARP and ATR inhibitors selectively kill A3A-expressing cells synergistically in a manner dependent on PrimPol-generated gaps. Thus, A3A-induced replication stress arises from PrimPol-generated ssDNA gaps, which confer a therapeutic vulnerability to gap-targeted DNA repair inhibitors.

27 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RKRehna Krishnan
Rehna Krishnan
PPParasvi S Patel
Parasvi S Patel
RHRazqallah Hakem
Razqallah Hakem
Heritable mutations in BRCA1 and BRCA2 genes are a major risk factor for breast and ovarian cancer. Inherited mutations in BRCA1 increase the risk of developing breast cancers by up to 72% and ovarian cancers by up to 69%, when compared to individuals with wild-type BRCA1. BRCA1 and BRCA2 (BRCA1/2) are both important for homologous recombination-mediated DNA repair. The link between BRCA1/2 mutations and high susceptibility to breast cancer is well established. However, the potential impact of BRCA1 mutation on the individual cell populations within a tumor microenvironment, and its relation to increased aggressiveness of cancer is not well understood. The objective of this review is to provide significant insights into the mechanisms by which BRCA1 mutations contribute to the metastatic and aggressive nature of the tumor cells.

2 August 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
KGKiran Kumar Naidu Guturi
Kiran Kumar Naidu Guturi
BGBrandon Gautreau
Brandon Gautreau
PPParasvi S Patel
Parasvi S Patel
ASAmine Saad
Amine Saad
RHRazq Hakem
Razq Hakem
The E3 ubiquitin ligase RNF8 plays critical roles in maintaining genomic stability by promoting the repair of DNA double-strand breaks (DSBs) through ubiquitin signaling. Abnormal activation of Notch signaling and defective repair of DSBs promote breast cancer risk. Here, we found that low expression of the full-length RNF8 correlated with poor prognosis for breast cancer patients. Our data revealed that in addition to its role in the repair of DSBs, RNF8 regulated Notch1 signaling and cell-fate determination of mammary luminal progenitors. Mechanistically, RNF8 acted as a negative regulator of Notch signaling by ubiquitylating the active NOTCH1 protein (N1ICD), leading to its degradation. Consistent with abnormal activation of Notch signaling and impaired repair of DSBs in Rnf8-mutant mammary epithelial cells, we observed increased risk of mammary tumorigenesis in mouse models for RNF8 deficiency. Notably, deficiency of RNF8 sensitized breast cancer cells to combination of pharmacological inhibitors of Notch signaling and poly(ADP-ribose) polymerase (PARP), suggesting implications for treatment of breast cancer associated with impaired RNF8 expression or function.

17 March 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PPParasvi S Patel
Parasvi S Patel
AAArash Algouneh
Arash Algouneh
RKRehna Krishnan
Rehna Krishnan
JRJohn J Reynolds
John J Reynolds
KNKevin C J Nixon
Kevin C J Nixon
RHRazqallah Hakem
Razqallah Hakem
BRCA1 mutations are associated with increased breast and ovarian cancer risk. BRCA1-mutant tumors are high-grade, recurrent, and often become resistant to standard therapies. Herein, we performed a targeted CRISPR-Cas9 screen and identified MEPCE, a methylphosphate capping enzyme, as a synthetic lethal interactor of BRCA1. Mechanistically, we demonstrate that depletion of MEPCE in a BRCA1-deficient setting led to dysregulated RNA polymerase II (RNAPII) promoter-proximal pausing, R-loop accumulation, and replication stress, contributing to transcription-replication collisions. These collisions compromise genomic integrity resulting in loss of viability of BRCA1-deficient cells. We also extend these findings to another RNAPII-regulating factor, PAF1. This study identifies a new class of synthetic lethal partners of BRCA1 that exploit the RNAPII pausing regulation and highlight the untapped potential of transcription-replication collision-inducing factors as unique potential therapeutic targets for treating cancers associated with BRCA1 mutations.

11 September 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RKRehna Krishnan
Rehna Krishnan
MLMariah Lapierre
Mariah Lapierre
BGBrandon Gautreau
Brandon Gautreau
KNKevin C J Nixon
Kevin C J Nixon
SGSamah El Ghamrasni
Samah El Ghamrasni
RHRazqallah Hakem
Razqallah Hakem
Breast cancer linked with BRCA1/2 mutations commonly recur and resist current therapies, including PARP inhibitors. Given the lack of effective targeted therapies for BRCA1-mutant cancers, we sought to identify novel targets to selectively kill these cancers. Here, we report that loss of RNF8 significantly protects Brca1-mutant mice against mammary tumorigenesis. RNF8 deficiency in human BRCA1-mutant breast cancer cells was found to promote R-loop accumulation and replication fork instability, leading to increased DNA damage, senescence, and synthetic lethality. Mechanistically, RNF8 interacts with XRN2, which is crucial for transcription termination and R-loop resolution. We report that RNF8 ubiquitylates XRN2 to facilitate its recruitment to R-loop-prone genomic loci and that RNF8 deficiency in BRCA1-mutant breast cancer cells decreases XRN2 occupancy at R-loop-prone sites, thereby promoting R-loop accumulation, transcription-replication collisions, excessive genomic instability, and cancer cell death. Collectively, our work identifies a synthetic lethal interaction between RNF8 and BRCA1, which is mediated by a pathological accumulation of R-loops.

8 January 2026 in Cancer Discovery
Verified
Journal Article
Open access
FCFerran Fece de la Cruz
Ferran Fece de la Cruz
AVAndreas Varkaris
Andreas Varkaris
PPParasvi S Patel
Parasvi S Patel
EKElijah W. Kushner
Elijah W. Kushner
AMAlvin A. Morales-Giron
Alvin A. Morales-Giron
RCRyan B. Corcoran
Ryan B. Corcoran
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620